Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Abatacept - Bristol-Myers Squibb

Drug Profile

Abatacept - Bristol-Myers Squibb

Alternative Names: BMS-188667; BMS-188667SC; CTLA4-Ig; hCTLA4-Ig-Bristol-Myers-Squibb; ONO-4164; ONO-4164-IV; ONO-4164-SC; Orencia; Orencia IV; Orencia SC

Latest Information Update: 06 Dec 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Bristol-Myers Squibb
  • Developer Bristol-Myers Squibb; Cambridge University Hospitals; Columbia University; National Institute of Allergy and Infectious Diseases; Ono Pharmaceutical; Simcere Pharmaceutical Group; University Hospital, Brest; University Medical Center Freiburg; University Medical Center Groningen; University of Michigan; University of Pittsburgh
  • Class Anti-inflammatories; Antipsoriatics; Antirheumatics; Drug conjugates; Eye disorder therapies; Immunoconjugates; Immunoglobulin fusion proteins; Skin disorder therapies
  • Mechanism of Action T cell activation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Juvenile rheumatoid arthritis; Psoriatic arthritis; Rheumatoid arthritis
  • Phase III Lupus nephritis; Myositis; Polymyalgia rheumatica; Sjogren's syndrome
  • Phase II Alopecia areata; Common variable immunodeficiency; Diffuse scleroderma; Graft-versus-host disease; Interstitial lung diseases; Nephrotic syndrome; Pulmonary sarcoidosis
  • No development reported Inflammation; Ulcerative colitis
  • Discontinued Crohn's disease; Multiple sclerosis; Psoriasis; Systemic lupus erythematosus; Transplant rejection; Xenotransplant rejection

Most Recent Events

  • 04 Dec 2019 Abatacept is still in phase II development for Graft-versus-host disease (Prevention, Combination therapy) in Canada, USA and (IV) (NCT01743131)
  • 04 Dec 2019 Abatacept receives Breakthrough Therapy status for Graft-versus-host disease (Prevention) in USA
  • 08 Nov 2019 Efficacy and adverse events data from a phase IIIb trial AVERT-2 in Rheumatoid arthritis released by Bristol-Myers Squibb
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top